Skip to content

Improvement of skeletal and muscle health in patients with sarcopenia by AIBEN YUEDONG Protein Nutrition Powder in combination with a resistance exercise intervention

Improvement of skeletal and muscle health in patients with sarcopenia by AIBEN YUEDONG Protein Nutrition Powder in combination with a resistance exercise intervention

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107172
Enrollment
Unknown
Registered
2025-08-05
Start date
2025-08-25
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sarcopenia

Interventions

Sponsors

Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for sarcopenia AWGS 2019 (i Grip strength less than 28.0 kg for males and less than 18.0 kg for females. ii 6-meter stride speed less than 1.0 m/s or 5-repetition sit-up test time >=12 seconds or SPPB <=9 points. iii BIA less than 7.0 kg/m^2 for males and 5.7 kg/m^2 for females or DXA less than 7.0 kg/m^2 for males and 5.4 kg/m^2 for females); 2. Age between 35-75 years old with high compliance; 3. Complete clinical data; 4. Voluntary participation in the program with informed consent and signing of the informed consent form.

Exclusion criteria

Exclusion criteria: 1. a clear history of allergy to protein powder in the past 6 months, or the presence of diarrhea symptoms and the frequency of >= 7 days / month, the duration of more than 2 weeks; 2. major physical diseases (diabetes with serious complications, malignant tumors, serious cardiovascular disease, neurological diseases or other diseases that may affect the effectiveness of exercise and nutritional interventions, etc.); 3. the past three months, new fractures and recently underwent joint replacement surgery patients; 4. Suffering from congenital bone or muscle diseases; 5. The simultaneous existence of other comorbidities affecting muscle metabolism, such as malignant tumors, liver disease, severe organ insufficiency such as nephrotic syndrome, renal failure and other diseases that may affect protein metabolism; 6. Participating in other clinical trials patients; 7. With sensory disabilities or other reasons significantly affecting the collection of data, such as severe deafness, blindness, mental disorders, etc.; 8. The researchers The researchers believe that other reasons are not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
Physical fitness;Appendicular skeletal muscle mass index;Non handgrip strength;6-minute walk test;Sit-to-stand test;Blood biochemical indices associated with sarcopenia;

Secondary

MeasureTime frame
Dietary intake status;General cognitive functioning;Sleep conditions;Daily living skills;Degree of knee injury;Bone mineral density;Knee joint structure and pathology;Serum-associated inflammatory factor;Intestinal flora species;Number of intestinal flora;Level of intestinal flora differentiation;blood lipids;fasting blood glucose;Insulin;Body composition;Height;weight;

Countries

China

Contacts

Public ContactWeiwei Ma

Capital Medical University

weiweima@ccmu.edu.cn+86 158 1030 7505

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026